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Dear Editor, 
It is acceptable to assume that the sport events globalization and increased mobility of elite athletes 
to endemic regions of infectious and viral diseases pose a risk to athletes and travelers. The risk of infectious 
diseases can be even higher in elite athletes due to their intense travel routine (Gärtner and Meyer, 2014) 
added to the exposure to different types of the environment where these athletes train (Turbeville et al., 
2006).  
Consequences of yellow fever infection could be serious: physical performance and health status not 
only can be compromised (Gärtner and Meyer, 2014), but also the athletes life can sometimes be at risk. For 
this reason we would like to draw attention to the risk of yellow fever in Brazil. 
According to the World Health Organization (WHO, 2017a), a few of the most developed and 
populated  Brazilian states (i.e. Minas Gerais, São Paulo, Bahia, Espírito Santo, and Rio de Janeiro) might be 
included in the considered endemic areas of yellow fever. Hence athletes, tourists, and spectators of sport 
events that travel to Brazil must  be aware of such a problem and be informed about recommendations,  
health prevention plans, and campaigns. 
Yellow fever is caused by a flavivirus, which is transmitted by an infected Aedes aegypti and 
Haemogogus mosquitoes. After the contagion, there is an incubation period of 3 to 6 days. The infection can 
occur in two phases with the following signs and symptoms (WHO, 2017b): 
- First (acute): fever, muscle pain, headache, shivers, appetite loss, nausea, and vomiting. In this case, 
most people get better after 3 to 4 days; 
- Second (15% of the cases, more toxic phase, fast progression, and approximately 24 hours of 
remission): high fever, multiple physiological systems affected, jaundice, abdominal pain, vomiting, 
bleeding mouth, nose and eyes, presence of blood in the vomit and feces, and kidney function deterioration. 
People who enter  this phase (50%) may die within 10 to 14 days.  
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There are three types of transmission:  
- Sylvatic (or jungle) - in tropical regions: the disease occurs in monkeys that pass the virus to 
mosquitoes. The infected mosquitoes bite humans who enter the forest; 
- Intermediate - common in some parts of Africa: semi-domestic mosquitoes infect monkeys and 
humans. Increased contact between people and infected mosquitoes leads to transmission; 
- Urban - epidemics in populated areas: infected mosquitoes transmit the virus from person to 
person (WHO, 2017b). 
The yellow fever diagnosis - normally obtained through blood tests (for the detection of antibodies) - 
is difficult in the early stages because it can be confused with other conditions such as poisoning and 
hemorrhagic fevers (e.g.: Zika and Dengue).  
Although there is no specific treatment for yellow fever, the disease can be prevented with 
vaccination (single dose provides life-long immunity) and mosquito control (eliminating sites of 
reproduction, killing adult mosquitoes and larvae with insecticides applied to places with high densities of 
mosquitoes, and encouraging community involvement in cleaning household drains and covering water 
containers) (WHO, 2017b). Preventive strategies to avoid contact with mosquitoes such as air-conditioned 
accommodation with screened windows and doors, insect repellents, and protective clothing can be quite 
effective  (Harley and Viennet, 2014; Ross, 2016) and therefore recommendable. Despite the lack of data on 
the matter we hypothesize that reported symptoms of yellow fever may affect sports performance for 
instance due to muscle impairment as demonstrated for Dengue and Zika infections (Brasil et al., 2016; 
Kalita et al., 2012; Misra et al., 2012).  
Considering how easy athletes and people can travel nowadays the promotion of preventive 
strategies and dissemination of accurate information about yellow fever are definitely necessary to help 
prevent infections among athletes if they decide to compete in a country with endemic areas such as Brazil. 
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